DOP2001000154A - Combinación de secretagogos de hormona del crecimiento y antidepresivos - Google Patents
Combinación de secretagogos de hormona del crecimiento y antidepresivosInfo
- Publication number
- DOP2001000154A DOP2001000154A DO2001000154A DO2001000154A DOP2001000154A DO P2001000154 A DOP2001000154 A DO P2001000154A DO 2001000154 A DO2001000154 A DO 2001000154A DO 2001000154 A DO2001000154 A DO 2001000154A DO P2001000154 A DOP2001000154 A DO P2001000154A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- prodrug
- procedures
- cases
- treatment
- medical procedure
- Prior art date
Links
- 239000000935 antidepressant agent Substances 0.000 title abstract 5
- 229940005513 antidepressants Drugs 0.000 title abstract 5
- 229940088597 hormone Drugs 0.000 title 1
- 239000005556 hormone Substances 0.000 title 1
- 238000000034 method Methods 0.000 abstract 7
- 239000000651 prodrug Substances 0.000 abstract 4
- 229940002612 prodrug Drugs 0.000 abstract 4
- 239000003112 inhibitor Substances 0.000 abstract 3
- 102100033367 Appetite-regulating hormone Human genes 0.000 abstract 2
- 101710111255 Appetite-regulating hormone Proteins 0.000 abstract 2
- 230000001430 anti-depressive effect Effects 0.000 abstract 2
- 239000003324 growth hormone secretagogue Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 abstract 2
- 229960002073 sertraline Drugs 0.000 abstract 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 abstract 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 208000036119 Frailty Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 102000010909 Monoamine Oxidase Human genes 0.000 abstract 1
- 108010062431 Monoamine oxidase Proteins 0.000 abstract 1
- 206010003549 asthenia Diseases 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000004217 heart function Effects 0.000 abstract 1
- 230000006996 mental state Effects 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 abstract 1
- 229960002748 norepinephrine Drugs 0.000 abstract 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 abstract 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 150000003335 secondary amines Chemical class 0.000 abstract 1
- 150000003512 tertiary amines Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Abstract
Esta invencion esta dirigida a combinaciones que comprenden un secretagogo de hormona del crecimiento, un profarmaco de este o una sal farmaceuticamente aceptable del citado secretagogo de la hormona de crecimiento o del citado profarmaco y un antidepresivo, un profarmaco de este o una sal farmaceuticamente aceptable del citado antidepresivo o del citado profarmaco y a composiciones farmaceuticas y estuches que comprenden dichas combinaciones. Los antidepresivos dentro del alcance de esta invención incluyen inhibidores de la recaptacion de norepinefrina (por ejemplo compuestos triciclicos con amina secundaria o terciaria) , inhibidores selectivos de la recaptacion de sertralina, agentes que son inhibidores de la recaptacion de norepinefrina/sertralina combinados, inhibidores de monoaminooxidasa y antidepresivos atipicos. Esta invencion ester dirigida tambien a procedimientos de mejora del estado fisico y/o psicologico de un paciente sometido a un procedimiento medico, a procedimientos de tratamiento de la fragilidad musculosesqueletica, a procedimientos de tratamiento de la insuficiencia cardiaca congestiva y a procedimientos de atenuacion de la respuesta catabblica proteinica despues de una operacibn importante, que comprenden la administracibn de dicha combinación. Particularmente, esta invencion se refiere composiciones y estuches tales que mejoran la función cardiaca, el metabolismo, el tono muscular y/o el estado mental de pacientes sometidos a un procedimiento medico. Las composiciones y estuches de esta invencion son tambien utiles para el tratamiento de trastornos del sistema nervioso central en pacientes sometidos a un procedimiento medico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20701700P | 2000-05-25 | 2000-05-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2001000154A true DOP2001000154A (es) | 2002-05-15 |
Family
ID=22768871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2001000154A DOP2001000154A (es) | 2000-05-25 | 2001-04-26 | Combinación de secretagogos de hormona del crecimiento y antidepresivos |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20020002137A1 (es) |
| EP (1) | EP1284753A2 (es) |
| JP (1) | JP2003534294A (es) |
| AR (1) | AR028620A1 (es) |
| AU (1) | AU2001255013A1 (es) |
| BR (1) | BR0111002A (es) |
| CA (1) | CA2408036A1 (es) |
| DO (1) | DOP2001000154A (es) |
| EC (1) | ECSP014082A (es) |
| GT (1) | GT200100089A (es) |
| MX (1) | MXPA02011554A (es) |
| PA (1) | PA8517701A1 (es) |
| PE (1) | PE20011262A1 (es) |
| SV (1) | SV2001000465A (es) |
| TN (1) | TNSN01076A1 (es) |
| UY (1) | UY26731A1 (es) |
| WO (1) | WO2001089570A2 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7795267B2 (en) | 2003-08-29 | 2010-09-14 | Takeda Pharmaceutical Company Limited | Bicyclic piperazine compound having TGR23 antagonistic activity |
| JP2005306839A (ja) * | 2003-08-29 | 2005-11-04 | Takeda Chem Ind Ltd | 二環性ピペラジン化合物およびその用途 |
| EP1757290A1 (en) | 2005-08-16 | 2007-02-28 | Zentaris GmbH | Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors |
| PE20080145A1 (es) * | 2006-03-21 | 2008-02-11 | Janssen Pharmaceutica Nv | Tetrahidro-pirimidoazepinas como moduladores de trpv1 |
| BRPI0807046A2 (pt) | 2007-02-09 | 2015-05-26 | Tranzyme Pharma Inc | Composto, composição farmacêutica, métodos de tratar um distúrbio, uma doença cardiovascular e um paciente que sofre de motilidade gastrointestinal reduzida ou disfuncional e, kit. |
| JP5647519B2 (ja) | 2007-09-13 | 2014-12-24 | コンサート ファーマシューティカルズ インコーポレイテッド | 重水素化カテコールおよびベンゾ［ｄ］［１，３］ジオキソールおよびその誘導体の合成 |
| PE20091102A1 (es) | 2007-12-17 | 2009-07-25 | Janssen Pharmaceutica Nv | Moduladores imidazolo-, oxazolo-, y tiazolopirimidina del trpv1 |
| EP2431035A1 (en) | 2010-09-16 | 2012-03-21 | Æterna Zentaris GmbH | Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors |
| AR086554A1 (es) | 2011-05-27 | 2014-01-08 | Novartis Ag | Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina |
| AU2013255458A1 (en) | 2012-05-03 | 2014-10-09 | Novartis Ag | L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists |
| CN116724038A (zh) | 2020-10-21 | 2023-09-08 | 安力高医药股份有限公司 | 双环化合物 |
| US11957683B2 (en) | 2021-06-18 | 2024-04-16 | Aligos Therapeutics, Inc. | Bicyclic compounds |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW432073B (en) * | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| AU7445498A (en) * | 1997-06-25 | 1999-01-04 | Pfizer Inc. | Dipeptide derivatives as growth hormone secretagogues |
-
2001
- 2001-04-26 DO DO2001000154A patent/DOP2001000154A/es unknown
- 2001-05-10 MX MXPA02011554A patent/MXPA02011554A/es unknown
- 2001-05-10 JP JP2001585812A patent/JP2003534294A/ja active Pending
- 2001-05-10 EP EP01928149A patent/EP1284753A2/en not_active Withdrawn
- 2001-05-10 AU AU2001255013A patent/AU2001255013A1/en not_active Abandoned
- 2001-05-10 WO PCT/IB2001/000815 patent/WO2001089570A2/en not_active Application Discontinuation
- 2001-05-10 BR BR0111002-0A patent/BR0111002A/pt not_active Application Discontinuation
- 2001-05-10 CA CA002408036A patent/CA2408036A1/en not_active Abandoned
- 2001-05-17 GT GT200100089A patent/GT200100089A/es unknown
- 2001-05-18 US US09/860,786 patent/US20020002137A1/en not_active Abandoned
- 2001-05-23 PE PE2001000472A patent/PE20011262A1/es not_active Application Discontinuation
- 2001-05-24 PA PA20018517701A patent/PA8517701A1/es unknown
- 2001-05-24 SV SV2001000465A patent/SV2001000465A/es unknown
- 2001-05-24 TN TNTNSN01076A patent/TNSN01076A1/fr unknown
- 2001-05-24 EC EC2001004082A patent/ECSP014082A/es unknown
- 2001-05-24 AR ARP010102481A patent/AR028620A1/es not_active Application Discontinuation
- 2001-05-25 UY UY26731A patent/UY26731A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2003534294A (ja) | 2003-11-18 |
| UY26731A1 (es) | 2001-12-28 |
| CA2408036A1 (en) | 2001-11-29 |
| WO2001089570A3 (en) | 2002-06-20 |
| EP1284753A2 (en) | 2003-02-26 |
| AU2001255013A1 (en) | 2001-12-03 |
| PA8517701A1 (es) | 2002-12-30 |
| MXPA02011554A (es) | 2003-04-25 |
| TNSN01076A1 (fr) | 2005-11-10 |
| ECSP014082A (es) | 2002-04-23 |
| WO2001089570A2 (en) | 2001-11-29 |
| BR0111002A (pt) | 2003-04-15 |
| US20020002137A1 (en) | 2002-01-03 |
| SV2001000465A (es) | 2001-07-03 |
| PE20011262A1 (es) | 2001-12-11 |
| GT200100089A (es) | 2002-01-11 |
| AR028620A1 (es) | 2003-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2317817C2 (ru) | Применение (1s,2r) энантиомера милнаципрана для получения лекарственного средства | |
| Asnis et al. | Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study | |
| Fava | New approaches to the treatment of refractory depression | |
| Detke et al. | Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial | |
| Nemeroff et al. | Duloxetine for the treatment of major depressive disorder | |
| Bellino et al. | Efficacy and tolerability of duloxetine in the treatment of patients with borderline personality disorder: a pilot study | |
| ECSP055839A (es) | COMPOSICIONES Y MÉTODOS PARA TRATAR LA ADMINISTRACIÓN MEJORADA POR VIA MUCOSA DE PÉPTIDOS FIJADORES AL RECEPTOR Y2 y MÉTODOS PARA TRATAR Y PREVENIR LA OBESIDAD | |
| DOP2001000154A (es) | Combinación de secretagogos de hormona del crecimiento y antidepresivos | |
| DE602006021444D1 (de) | Therapie zur behandlung der überaktiven blase | |
| EA200600820A1 (ru) | Способы лечения, модификации и устранения боли с использованием 1-оксо-2-(2,6-диоксопиперидин-3-ил)-4-метилизоиндолина | |
| UY27533A1 (es) | Composiciones farmacéuticas que contienen oxibutinina | |
| RU2214824C2 (ru) | Комбинация ингибитора обратного захвата 5-ht и антагониста или частичного агониста h5-ht1b | |
| Nelson et al. | The safety and tolerability of duloxetine compared with paroxetine and placebo: a pooled analysis of 4 clinical trials | |
| NO20055531L (no) | Preparat for forbedret kognisjon og hukommelse | |
| TWI250872B (en) | Carbamate compounds for use in preventing or treating bipolar disorder | |
| CO5540290A2 (es) | Composicion que comprende un inhibidor de pde-4 y antagonista del receptor-hi y su uso en la manufactura de un medicamento para el tratamiento de enfermedades respiratorias | |
| ES2625142T3 (es) | Usos terapéuticos de 1-[2-(2,4-dimetil-fenilsulfanil)fenil]-piperacina | |
| HUP0302436A2 (hu) | Antidepresszáns gyógyszerek által kiváltott szexuális rendellenességek kezelése apomorfinnal | |
| AR029666A1 (es) | Uso del (+) -alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-piperidinmetanol o su prodroga para la manufactura de un medicamento en el tratamiento de los sintomas de la demencia y de la psicosis inducida por dopamina | |
| AR012751A1 (es) | Sales de hidrogeno tartrato de (r) -3-n,n-diciclobutilamino-8-fluoro-3,4 -dihidro-2h-1-benzopiran-5-carboxamida, su uso para la fabricacion de medicamentos para tratar trastornos de snc y trastornos medicos relacionados y procedimiento para la fabricacion de dichas sales | |
| RU2005131578A (ru) | Аплидин для лечения множественной миеломы | |
| JP5634529B2 (ja) | 強迫性障害（ｏｃｄ）処置用の薬剤の製造のためのアゴメラチンの使用 | |
| Tan et al. | Efficacy and tolerability of vardenafil in Asian men with erectile dysfunction | |
| Vercellino et al. | A comprehensive review of the use of antipressants drugs in Major Depressive Disorder and Sexuality | |
| BR9913765A (pt) | Composição, uso da composição, método para o tratamento de distúrbios mediados por 5-ht, método de melhoria do inìcio da ação terapêutica, formulação farmacêutica, processo para a preparação da composição, e, kit |